Identifying clinical net benefit of psychotropic medication use with latent variable techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

•Develop and validated a novel construct of clinical net benefit of treatment for BD.•Latent variable techniques found unique groups of benefit in a BD population.•There is substantial heterogeneity in benefit experienced during treatment for BD.•Construct validity was supported by SF-36 scores dete...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of affective disorders 2018-10, Vol.238, p.147-155
Hauptverfasser: Bareis, Natalie, Lu, Juan, Kirkwood, Cynthia K., Kornstein, Susan G., Wu, Elwin, Mezuk, Briana
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Develop and validated a novel construct of clinical net benefit of treatment for BD.•Latent variable techniques found unique groups of benefit in a BD population.•There is substantial heterogeneity in benefit experienced during treatment for BD.•Construct validity was supported by SF-36 scores determined for each unique group.•Despite low benefit, medication adherence was similar in high and low benefit groups. Poor medication adherence is common among individuals with Bipolar Disorder (BD). Understanding the sources of heterogeneity in clinical net benefit (CNB) and how it is related to psychotropic medications can provide new insight into ways to improve adherence. Data come from the baseline assessments of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Latent class analysis identified groups of CNB, and validity of this construct was assessed using the SF-36. Adherence was defined as taking 75% or more of medications as prescribed. Associations between CNB and adherence were tested using multiple logistic regression adjusting for sociodemographic characteristics. Five classes of CNB were identified: High (24%), Moderately high (12%), Moderate (26%), Moderately low (27%) and Low (12%). Adherence to psychotropic medications did not differ across classes (71% to 75%, χ2 = 3.43, p = 0.488). Medication regimens differed by class: 57% of the High CNB were taking ≤2 medications, whereas 49% of the Low CNB were taking ≥4. CNB classes had good concordance with the SF-36. Missing data limited measures used to define CNB. Participants’ perceptions of their illness and treatment were not assessed. This novel operationalization of CNB has construct validity as indicated by the SF-36. Although CNB and polypharmacy regimens are heterogeneous in this sample, adherence is similar across CNB. Studying adherent individuals, despite suboptimal CNB, may provide novel insights into aspects influencing adherence.
ISSN:0165-0327
1573-2517
DOI:10.1016/j.jad.2018.05.063